Skip to main content
MarketsReportedMedium
5.1

Eli Lilly to Acquire Calytrix Bio for $1.5B in Blood Cancer Bet

Eli Lilly has agreed to acquire Calytrix Bio, a blood cancer-focused biotech founded in 2025 by JP Morgan Life Sciences Private Capital, for $1.5 billion. The deal underscores Lilly's strategic pivot toward oncology, a departure from its traditional metabolic disease focus. Financial terms and regulatory timeline remain undisclosed, but the acquisition signals continued M&A activity in the biotech sector.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works

La República3 days agoUSCredibility 28%View source

Score Breakdown

Mosaic Score5.1
Model confidence0.7
Significance0.5
Source credibility0.3

Intelligence Tags

Entities

United Statescountry
Source

Related signals

8 found